CD8A and neoplasm: An mRNA platform that fuses antigens to a proteasome-targeting peptide enhanced antigen destruction through the ubiquitin–proteasome system, boosted genes in the MHC-I pathway, and generated stronger CD8+ T-cell responses in vivo, with increased dendritic/macrophage activation, intratumoral T-cell infiltration, tumor growth delay, and durable memory (53).